Grocery business Publix said on Tuesday that its is suspending the administration of the Johnson & Johnson COVID-19 vaccine at all of its pharmacy locations following guidance from the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA).
The CDC and FDA have issued a joint media statement with additional information about the Johnson & Johnson COVID-19 vaccine.
While a rare side effect, individuals who have received the Johnson & Johnson COVID-19 vaccine should contact their health care provider if they develop a severe headache, abdominal pain, leg pain or shortness of breath within three weeks, according to the CDC and FDA.
However, the customers can visit publix.com/covidvaccine to schedule an appointment for the Moderna COVID-19 vaccine, if currently available in their state.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval